Citadel Advisors’s Applied Therapeutics APLT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-135,000
| Closed | -$13.5K | – | 12921 |
|
|
2025
Q4 | $13.5K | Sell |
135,000
-33,500
| -20% | -$21.3K | ﹤0.01% | 12408 |
|
|
2025
Q3 | $102K | Buy |
168,500
+20,100
| +14% | +$9.47K | ﹤0.01% | 11843 |
|
|
2025
Q2 | $46.2K | Sell |
148,400
-16,900
| -10% | -$6.54K | ﹤0.01% | 11812 |
|
|
2025
Q1 | $80.8K | Sell |
165,300
-70,000
| -30% | -$41.2K | ﹤0.01% | 11748 |
|
|
2024
Q4 | $201K | Buy |
235,300
+216,300
| +1,138% | +$1.36M | ﹤0.01% | 10448 |
|
|
2024
Q3 | $162K | Buy |
19,000
+11,100
| +141% | +$65.4K | ﹤0.01% | 10466 |
|
|
2024
Q2 | $36.9K | Buy |
7,900
+800
| +11% | +$3.79K | ﹤0.01% | 12068 |
|
|
2024
Q1 | $48.3K | Sell |
7,100
-6,900
| -49% | -$31K | ﹤0.01% | 12205 |
|
|
2023
Q4 | $46.9K | Buy |
14,000
+13,900
| +13,900% | +$34.6K | ﹤0.01% | 11842 |
|
|
2023
Q3 | $249 | Sell |
100
-500
| -83% | -$824 | ﹤0.01% | 14116 |
|
|
2023
Q2 | $768 | Buy |
+600
| New | +$796 | ﹤0.01% | 14051 |
|
|
2023
Q1 | – | Sell |
-100
| Closed | -$76 | – | 14665 |
|
|
2022
Q4 | $76 | Buy |
+100
| New | +$79 | ﹤0.01% | 14769 |
|
|
2022
Q3 | – | Sell |
-17,200
| Closed | -$16K | – | 12541 |
|
|
2022
Q2 | $16K | Sell |
17,200
-9,000
| -34% | -$14.7K | ﹤0.01% | 12475 |
|
|
2022
Q1 | $55K | Buy |
26,200
+14,800
| +130% | +$39.6K | ﹤0.01% | 12728 |
|
|
2021
Q4 | $102K | Buy |
+11,400
| New | +$150K | ﹤0.01% | 12701 |
|
Citadel Advisors's APLT Position: Q3 2025 in Review
Citadel Advisors sold out of Applied Therapeutics (APLT) in Q3 2025, closing a stake of 474,094 shares — an estimated $223K sold.
Citadel Advisors first reported a position in APLT in Q1 2020 and held it in 15 quarters. The position peaked at $3M in Q3 2024. 70 funds tracked by Wall St. Rank hold APLT as of Q3 2025.
- Citadel Advisors reported no remaining Applied Therapeutics position as of Q3 2025 after selling out during the quarter.
- Citadel Advisors sold 474,094 Applied Therapeutics shares in Q3 2025, an estimated $223K.
- Citadel Advisors first reported a position in Applied Therapeutics in Q1 2020 and held it in 15 quarters.
- Citadel Advisors's Applied Therapeutics position peaked at $3M in Q3 2024.
- 70 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.